Navigation Links
Pacira Pharmaceuticals Names David M. Stack CEO and President
Date:12/18/2007

SAN DIEGO, Dec. 18 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., a leader in sustained release injectable technologies, today announced that David M. Stack has been selected as President, Chief Executive Office, and member of the Board of Directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOGO)

Mr. Stack is currently the CEO and founding partner of Stack Pharmaceuticals, Inc., a commercialization, marketing and strategy firm serving emerging healthcare companies. He also is an Executive Partner at MPM Capital.

"David Stack is a proven, successful pharmaceutical executive with an exceptional blend of leadership and business skills," said Fred Middleton, Chairman of the Board. "We are confident that he is the ideal person to lead Pacira by enhancing the revenue opportunities of our existing commercial products, DepoDur and DepoCyt, optimizing the development and launch of our key asset, DepoBupivacaine, while further exploring the untapped promise of our proprietary drug delivery technologies."

Commenting on his appointment, Mr. Stack said, "I look forward to joining Pacira at this exciting time in its history. With strong financial backing by a pharmaceutical experienced syndicate, Pacira now has the opportunity to realize its potential by growing into a fully integrated, successful commercial company."

From September 2001 until August 2004, Mr. Stack was President, Chief Executive Officer and Director of The Medicines Company (Nasdaq: MDCO). Prior to The Medicines Company he was the CEO of Stack Pharmaceuticals, Inc. where MDCO was one of the primary customers.

From May 1995 to December 1999, Mr. Stack served as the President and General Manager of Innovex, Inc. and was responsible for the Americas. Innovex, Inc. is a commercial solutions company offering a full range of marketing, sales and clinical development capabilities to pharmaceutical and biotechnology customers.

Mr. Stack's prior experience also includes serving as the Vice President of Business Development and Marketing for Immunomedics, Inc. (Nasdaq: IMMU), as well as multiple senior business management positions at Roche Labs. Before he entered the commercial pharmaceutical sector, Mr. Stack was a retail and hospital pharmacist for three years after graduating from Albany College of Pharmacy. He also holds a BS in Biology from Siena College. Dave was recognized as the Ernst and Young Entrepreneur of the Year in 2003 (New Jersey Healthcare). He is a Director of Bio-Imaging Technologies, Inc. (Nasdaq: BITI), Medsite, Inc., PepTx, Inc. and QRxPharma Pty Ltd.

About Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc. is a wholly owned subsidiary of Pacira Inc., a Delaware corporation, which is controlled and funded by a group of financial investors including HBM BioVentures (Cayman) Ltd., MPM Capital, OrbiMed Advisors, and Sanderling Ventures. This business is based in San Diego, CA, and formulates, develops and manufactures controlled-release injectable products based on two proprietary drug delivery platforms: DepoFoam(R) and Biosphere(R). Revenues are generated from two marketed products: DepoCyt(R) for lymphomatous meningitis and DepoDur(R) for the treatment of post-surgical pain. For additional information about Pacira visit the Company's website at http://www.pacira.com


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
Breaking Medicine Technology: